Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update

Reviews on Recent Clinical Trials

Volumn 3, Issue 3, 2008, Pages 212-216

  Kruck, Stephan ^a   Kuczyk, Markus A ^b   Gakis, Georgios ^a   Kramer, Mario W ^a   Stenzl, Arnulf ^a   Merseburger, Axel S ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antiangiogenic agents; ASCO 2007; Combination regime; Renal cell carcinoma; Targeted therapies; Tyrosine kinase inhibitor

Indexed keywords

AXITINIB; BEVACIZUMAB; CEDIRANIB; ERLOTINIB; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; PAZOPANIB; PERIFOSINE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VATALANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; INDOLE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; RAPAMYCIN; VASCULOTROPIN A;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ASTHENIA; BLEEDING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTESTINE PERFORATION; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PAIN; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; VOICE CHANGE; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY TUMOR; METASTASIS; ORGANIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; HUMANS; INDOLES; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 54049131744     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488708785700311     Document Type: Review

References (37)

1. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92: 1855-61.
2. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16: 1688-94.
3. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12.
4. Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol (Meeting Abstracts) 2007; 25: 5025.
5. Amato RJ, Harris P, Dalton M, et al. A phase II trial of intrapatient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol (Meeting Abstracts) 2007; 25: 5026.
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in Advanced Clear-Call Renal-Cell Carcinoma. N Engl J Med 2007; 356: 125-34.
7. Gondek K, Dhanda R, Simantov R, Gatzemeier U, Blumenschein GR, Reck M. Health-related quality of life measures in advanced non-small cell lung cancer patients receiving sorafenib. J Clin Oncol (Meeting Abstracts) 2006; 24: 17085.
8. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
9. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-24.
10. Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2006; 24: 4522.
11. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
12. Srinivas S, Roigas J, Gillessen S, et al. Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC: Updated results. J Clin Oncol (Meeting Abstracts) 2007; 25: 5040.
13. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006; 12: 7215-20.
14. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
15. Amato RJ, Misellati A, Khan M, Chiang S. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol (Meeting Abstracts) 2006; 24: 4530.
16. Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol (Meeting Abstracts) 2007; 25: 5107.
17. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
18. Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/ interferon-{alpha}2a vs placebo/interferon- {alpha}2a as firstline therapy in metastatic renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2007; 25: 3.
19. Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol (Meeting Abstracts) 2007; 25: 5031.
20. Sridhar SS, Hotte SJ, Mackenzie MJ, et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium. J Clin Oncol (Meeting Abstracts) 2007; 25: 5093.
21. Rini BI, Wilding GT, Hudes G, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol (Meeting Abstracts) 2007; 25: 5032.
22. Stephenson J, Schreeder M, Waples J, et al. Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI). J Clin Oncol (Meeting Abstracts) 2007; 25: 15622.
23. Sosman JA, Flaherty K, Atkins MB, et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC patients (Pts). J Clin Oncol (Meeting Abstracts) 2006; 24: 3031.
24. Ryan CW, Goldman BH, Lara PN, Jr., et al. Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group. J Clin Oncol 2007; 25: 3296-301.
25. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23: 7889-96.
26. Feldman DR, Kondagunta GV, Ronnen EA, et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2007; 25: 5099.
27. Merchan JR, Liu G, Fitch T, et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J Clin Oncol (Meeting Abstracts) 2007; 25: 5034.
28. Speca JC, Mears AL, Creel PA, et al. Phase I study of PTK787/ ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients. J Clin Oncol (Meeting Abstracts) 2007; 25: 5039.
29. Tamaskar I, Shaheen P, Wood L, et al. Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. J Clin Oncol (Meeting Abstracts) 2006; 24: 4597.
30. Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol (Meeting Abstracts) 2007; 25: 5038.
31. Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2007; 25: 5106.
32. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27: 187-93.
33. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-8.
34. Fossa SD, Mickisch GH, De Mulder PH, et al. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 2004; 101: 533-40.
35. Dhanda R, Gondek K, Song J, Cella D, Bukowski RM, Escudier B. A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. J Clin Oncol (Meeting Abstracts) 2006; 24: 4534.
36. Gao X, Reddy P, Dhanda R, et al. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2006; 24: 4604.
37. Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22: 1188-94.